Research groups

GC02 Oxidative and Nitrosative stress in acute and chronic liver disease

Our research group is a consolidated multidisciplinary team composed of 6 basic researchers and 8 clinicians. The group is involved in the scientific education of its members, which is reflected in the 4 post-doctoral and 3 pre-doctoral researchers, who are developing their scientific career in the group. Besides, we have the valuable support of 3 dedicated nurses trained in research tasks. 

Our main research area is the molecular basis of liver and digestive diseases, with special dedication to patients with end-stage liver disease who develop hepatocellular carcinoma or undergo liver transplantation, and patients with inflammatory bowel diseases.

In the long term, we expect to apply the results of our research projects to develop a more personalized medicine, increasing the efficacy of the treatments and their safety. In particular, we are continuously working in improving immunosuppression regimens for liver transplant patients and in implementing liquid biopsy as a prognostic tool to select patients with hepatocellular carcinoma to undergo liver transplantation. In inflammatory bowel diseases, we expect to apply the identified biomarkers of response to anti-TNF to select the best treatment for each patient. The group aims to promote and to protect the health through the basic, clinical and translational research in liver and digestive diseases. In addition, our group is deeply engaged in providing access to the novel therapies to our patients, as part of our participation in 45 trials in hepatology and inflammatory bowel diseases in the last 10 years.

Regarding immunosuppression strategies, in the past few years we have shown that early minimization of tacrolimus in liver transplant patients with hepatocellular carcinoma is able to decrease tumor recurrence rates, while prolonging graft survival (Journal of Hepatology, 2013) and preserving renal function (Am J Transplant 2012 and Transplantation 2019). We have also demonstrated that everolimus, an mTOR inhibitor, may be safely introduced early after liver transplantation (Transplant Immunol, 2015) and may allow a safe minimization of tacrolimus, although without a significant effect against recurrence of hepatocellular carcinoma (Transplantation 2018). Early in 2017 we have worked with the Cochrane Collaboration to perform a network meta-analysis to make a ranking of the most effective and safest immunosuppression protocols (Cochrane Syst Rev Database, 2017). The results have reinforced the assumption that tacrolimus based immunosuppression is the gold standard after liver transplantation, even though its optimal combination with other immunosuppressants remains unknown. Further research initiatives are needed in order to accomplish a true personalized immunosuppression (Transplant International, 2016).

Research Lines

Hepatocellular carcinoma and liver transplantation: Patients with hepatocellular carcinoma confined into the liver are sometimes candidates for liver transplantation, resulting in a dramatic improvement of life expectancy. However, around 15% of patients will develop tumor recurrence after transplantation. In order to avoid this complication, we are evaluating the role of a novel diagnostic tool (liquid biopsy) to refine the selection of liver transplant candidates, while delineating personalized immunosuppression protocols (CNI minimization/mTOR inhibition) able to avoid graft rejection without hampering the anti-tumor capacity of the immune system.

Recently, the SNP rs6105269 has been identified as risk factor for Crohn’s Disease. Our group has analyzed the expression of the closest genes to polymorphism, MACROD2 and FLRT3, in order to clarify if they are affected by the SNP. Beside, we have analysed if the SNP is a prognosis marker of the disease.

We have 2 active projects, in Crohn's disease and ulcerative colitis, that aim to identify plasma biomarkers of response to anti-TNF using an advanced proteomic approach, named SWATH.

Our group is strongly committed to participate in the development of novel drugs for patients with advanced hepatocellular carcinoma. In this research line, we are continuously involved in randomized phase I/II clinical trials.

We have recently proposed the SR11302 synthetic retinoid as a promising therapeutic agent using a model of cholestasis in vitro. We are interested to assay this retinoid in a model of cholestasis in vivo.

We are using liquid biopsy to study the kinetic of CTCs release in patients with hepatocellular carcinoma undergoing loco-regional ablative therapies and to identify the subpopulation of circulating cancer stem cells (CSCs) after the application of ablative therapies as an early prognostic marker to know the biologic behavior of the tumor.

Networks

    Our group is a member of "Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)", which is a national platform formed by outstanding research groups in the area. In addition, our group is member of "Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)", promoting our collaboration in numerous studies with the most important Inflammatory Bowel Disease Units of Spain. One of these projects is the national database and genetic samples biobank, named ENEIDA.

    In addition, the research team is part of the scientific groups CTS-273 in Study of acute affections of the digestive system, and BIO-216 on Molecular mechanisms of antioxidant and proteomic defense, both pertaining to the Andalusian Plan for Research, Development and Innovation (PAIDI).

Keywords

  • Liver transplant
  • hepatocellular carcinoma
  • Crohn's disease
  • ulcerative colitis
  • cholestasis
  • liquid biopsy
  • proteomic
  • anti-TNF

GC02 Oxidative and Nitrosative stress in acute and chronic liver disease

Principal Investigator
Manuel de la Mata García

Co-Principal Investigator
Jose Antonio Bárcena Ruíz

Researchers
Patricia Aguilar Melero
Pilar Barrera Baena
Guadalupe Costán Rodero
Gustavo Ferrín Sánchez
Mª Valle García Sánchez
José Luis Montero Álvarez
Alicia Padilla Peña
José Peinado Peinado
Antonio Poyato González
Manuel Luis Rodríguez Perálvarez

Post-Doctoral Researchers
Sandra González Rubio
Clara Isabel Linares Luna
Raquel Requejo Aguilar
Luis Vida Pérez

Pre-Doctoral Researchers
José Manuel Benítez Cantero
Rocio Fernández Gonález
Marta Guerrero Misas
Eva Iglesias Flores
Rosario Medina Medina

Nursing, Technical, and Administrative Staff
Encarna Díaz Sillero
Mª Isabel Gómez Núñez
Mª Isabel Salgueiro Rodríguez

Projects

Active projects

Local

Bárcena Ruiz, JA; BIO-216 Sistemas moleculares de defensa frente al estrés oxidativo y proteómica; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: P.P. 2019 Subm. 1.1. (BIO-216).

Requejo Aguilar, R, Efecto de los sistemas antioxidantes Prdx6 y DJ-1 sobre la función mitocondrial: Influencia en la supervivencia celular. Funding Agency: UNIVERSIDAD DE CORDOBA; Reference:  P.P. 2019 Submod. 2.6

Guerrero Misas, M; Stop Fuga Cerebros/Marta Guerrero/Aparato Digestivo; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: SFC17/04

Regional

Requejo Aguilar, R, La enfermedad de Parkinson como enfermedad metabólica originada por disfunción mitocondrial. Funding Agency: JUNTA DE ANDALUCÍA, Programa Operativo FEDER Andalucía 2014-2020; Reference: 1262530-R

National

De la Mata García, M. & Ferrín Sánchez, G. Release of circulating tumor cells after local ablation of hepatocellular carcinoma. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI18/01736.

Publications

Publications 2019

Lopez-Grueso MJ, Gonzalez-Ojeda R, Requejo-Aguilar R, McDonagh B, Fuentes-Almagro CA, Muntane J, Barcena JA, Padilla CA. Thioredoxin and glutaredoxin regulate metabolism through different multiplex thiol switches. REDOX BIOLOGY. 2019. 21. DOI:10.1016/j.redox.2018.11.007.
IF: 7,793
Q: 1  D: 1

Bonzon-Kulichenko, Elena, Emilio Camafeita, Juan Antonio López, María Gómez-Serrano, Inmaculada Jorge, Enrique Calvo, Estefanía Núñez, et al. “Improved Integrative Analysis of the Thiol Redox Proteome Using Filter-Aided Sample Preparation.” Journal of Proteomics 2020 Mar 1;214:103624.  doi: 10.1016/j.jprot.2019.103624.
IF: 3,537
Q: 1

López-Grueso MJ, González R, Muntané J, Bárcena JA, Padilla CA. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. Antioxidants. 2019. 8 (10): 501. https://doi.org/10.3390/antiox8100501.
IF: 4,520
Q: 1

López-Grueso MJ, Tarradas Valero RM, Carmona-Hidalgo B, Lagal DJ, Perinado J, McDonagh B, Requejo-Aguilar R, Bárcena JA, Padilla CA. “Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells.” Antioxidants. 2019 Oct 23;8(11). pii: E505. doi: 10.3390/antiox8110505.
IF: 4,520
Q: 1

Padilla CA, Bárcena JA, López-Grueso MJ, Requejo-Aguilar R. The Regulation of TORC1 Pathway by the Yeast Chaperones Hsp31 Is Mediated by SFP1 and Affects Proteasomal Activity.” Biochimica et Biophysica Acta - General Subjects. 2019. 1863 (3). https://doi.org/10.1016/j.bbagen.2018.12.011.
IF: 3,681
Q: 2

Picazo C, McDonagh B, Peinado J, Bárcena JA, Matallana E, Aranda A. Saccharomyces Cerevisiae Cytosolic Thioredoxins Control Glycolysis, Lipid Metabolism, and Protein Biosynthesis under Wine-Making Conditions. Applied and Environmental Microbiology. 2019. 85 (7). https://doi.org/10.1128/AEM.02953-18.
IF: 4,077
Q: 1

Rodriguez-Peralvarez M, Amado V, de la Mata M. Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2019. 50. 4. 478-479. DOI:10.1111/apt.15300.
IF: 7,731
Q: 1  D: 1

Garrido-Rodriguez M, Ortea I, Calzado MA, Munoz E, Garcia V. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. JOURNAL OF PROTEOMICS. 2019. 193. 217-229. DOI:10.1016/j.jprot.2018.10.012.
IF: 3,537
Q: 1

Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019. 20. 2. DOI:10.3390/ijms20020336.
IF: 4,183
Q: 2

Padilla CA, Barcena JA, Lopez-Grueso MJ, Requejo-Aguilar R. The regulation of TORC1 pathway by the yeast chaperones Hsp31 is mediated by SFP1 and affects proteasomal activity. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS. 2019. 1863. 3. 534-546. DOI:10.1016/j.bbagen.2018.12.011.
IF: 3,681
Q: 2

Amado V, Rodriguez-Peralvarez M, Ferrin G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. JOURNAL OF HEPATOCELLULAR CARCINOMA. 2019. 6. 1-10. DOI:10.2147/JHC.S174549.

Main Publications 2018

Rodriguez-Peralvarez M, Guerrero M, Barrera L, Ferrin G, Alamo JM, Ayllon MD, Artacho GS, Montero JL, Briceno J, Bernal C, Padillo J, Marin-Gomez LM, Pascasio JM, Poyato A, Gomez-Bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. TRANSPLANTATION. 2018; 102(12):2056-2064.
IF: 3,96  
Q: 1  D: 1

Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV.Post-colonoscopy colorectal cancer: Characteristics and predictive factors. MEDICINA CLINICA.2018.150(1)1-7.
IF:1,168  
Q: 3

Alayon CG, Crespo CP, Pedrosa SM, Benítez  J, Flores E, Rodriguez I, Medina R, Garcia-Sanchez V. Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life. GASTROENTEROLOGIA Y HEPATOLOGIA. 2018; 41(1):22-29.
IF: 1,078  
Q: 4

Other Publications 2018

Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Biron IA, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Shitrit ABG, Gutierrez A, Doherty GA, Fernandez-Salazar L, Cadilla JM, Huguet JM, O'Toole A, Stasi E, Marcos NM, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Palomares MDL, Fiorino G, Benítez  JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Bradley IF, Roman ALS, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, de Carpi FJM, Gisbert JP. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2018; 113(3):396-403.
IF: 10,231  
Q: 1   D: 1

Ordas I, Domenech E, Manosa M, Garcia-Sanchez V, Iglesias-Flores E, Rodriguez-Moranta F, Marquez L, Merino O, Fernandez-Banares F, Gomollon F, Vera M, Gutierrez A, LLao J, Gisbert JP, Aguas M, Arias L, Rodriguez-Lago I, Munoz C, Alcaide N, Calvet X, Rodriguez C, Montoro MA, Garcia S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panes J, Esteve M. Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2018; 113(7):1009-1016.
IF: 10,231  
Q: 1   D: 1

Fernandez-Fernandez S, Bobo-Jimenez V, Requejo-Aguilar R, Gonzalez-Fernandez S, Resch M, Carabias-Carrasco M, Ros J, Almeida A, Bolanos JP. Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function. REDOX BIOLOGY. 2018; 19:52-61.
IF: 7,126  
Q: 1

Gonzalez R, Molina-Ruiz FJ, Barcena JA, Padilla CA, Muntane J. Regulation of Cell Survival, Apoptosis, and Epithelial-to-Mesenchymal Transition by Nitric Oxide-Dependent Post-Translational Modifications.ANTIOXIDANTS & REDOX SIGNALING. 2018; 29(13):1312-1332.
IF: 6,53  
Q: 1   D: 1

Domenech E, Panes J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernandez F, Gonzalez-Conde B, Garcia-Sanchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. JOURNAL OF CROHNS & COLITIS. 2018; 12(6):687-694.
IF: 6,637  
Q: 1

Taxonera C, Ponferrada A, Riestra S, Bermejo F, Saro C, Martin-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, Lopez-Serrano P, Barrio J, Suarez C, Iglesias E, Arguelles-Arias F, Ferrer I, Marin-Jimenez I, Hernandez-Camba A, Bastida G, Van Domselaar M, Martinez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes O, Merino O, Alba C, Gisberty JP, Martin-Rodriguez MD, Botella B, Carpio D, Ceballos D, Verdejo C, Morales I, Legido J, Penate M, Chaparro M, Algaba A, de Francisco R. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. JOURNAL OF CROHNS & COLITIS. 2018; 12(11):1270-1279.
IF: 6,637  
Q: 1

Manzardo C, Londono MC, Castells L, Testillano M, Montero JL, Penafiel J, Subirana M, Moreno A, Aguilera V, Gonzalez-Dieguez ML, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Sousa JM, Suarez F, Serrano T, Herrero JI, Jimenez M, Fernandez JR, Gimenez C, del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. AMERICAN JOURNAL OF TRANSPLANTATION. 2018; 18(10):2513-2522.
IF: 6,493  
Q: 1   D: 1

Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(11):1218-1219.
IF: 5,394  
Q: 1   D: 1

Frontinan-Rubio J, Santiago-Mora RM, Nieva-Velasco CM, Ferrin G, Martinez-Gonzalez A, Gomez MV, Moreno M, Ariza J, Lozano E, Arjona-Gutierrez J, Gil-Agudo A, De la Mata M, Pesic M, Peinado JR, Villalba JM, Perez-Romasanta L, Perez-Garcia VM, Alcain FJ, Duran-Prado M. Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.RADIOTHERAPY AND ONCOLOGY.  2018; 128(2):236-244.
IF: 4,942  
Q: 1

Paez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortun J, Len O, Abdala E, Farinas MC, Cordero E, de Gracia C, Hernandez D, Gonzalez R, Torre-Cisneros J, Cantisan S. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG + response. ANTIVIRAL RESEARCH. 2018; 155:97-105.
IF: 4,307  
Q: 1

Ayllon MD, Ciria R, Cruz-Ramirez M, Perez-Ortiz M, Gomez I, Valente R, O'Grady J, de la Mata M, Hervas-Martinez C, Heaton ND, Briceno J. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. LIVER TRANSPLANTATION. 2018; 24(2):192-203.
IF: 3,752  
Q: 1

Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. JOURNAL OF HEPATOLOGY. 2018; 68(5):940-948. doi: 10.1016/j.jhep.2017.12.019.
IF: 15,040   
Q: 1  D: 1

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018 Oct;48(8):839-851. doi: 10.1111/apt.14930.
IF: 7,357
Q: 1  D: 1

Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, Cabello MR, Robles-Diaz M, Sanabria-Cabrera J, Sanjuan-Jimenez R, Ortega-Alonso A, García-Muñoz B, Moreno I, Jimenez-Perez M, Fernandez MC, Ginés P, Prieto M, Conde I, Hallal H, Soriano G, Roman E, Castiella A, Blanco-Reina E, Montes MR, Quiros-Cano M, Martin-Reyes F, Lucena MI, Andrade RJ; Spanish DILI Registry. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology. 2018; 16(9):1495-1502. doi: 10.1016/j.cgh.2017.12.051.
IF: 7,683  
Q: 1  D: 1

Garcia-Planella E, Manosa M, Chaparro M, Beltran B, Barreiro-de-Acosta M, Gordillo J, Ricart E, Bermejo F, Garcia-Sanchez V, Piqueras M, Llao J, Gisbert JP, Cabre E, Domenech E. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2018; 53(2):152-157.
IF: 2,629  
Q: 3

Ciria R, Navarro E, Sanchez-Frias M, Gallardo AB, Medina J, Ayllon MD, Gomez-Luque I, Ruiz-Rabelo J, Luque A, de la Mata M, Rufian S, Lopez-Cillero P, Briceno J. Preliminary results from the use of intraoperative real-time biliary oxygen monitoring in liver transplantation. CLINICAL TRANSPLANTATION. 2018; 32(12):Núm artículo e13433
IF: 1,518  
Q: 3

Rodriguez-Lago I, Benítez  JM, Garcia-Sanchez V, Gutierrez A, Sempere L, Ginard D, Barreiro-de Acosta M, Cabriada JL. Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients' point of view. GASTROENTEROLOGIA Y HEPATOLOGIA. 2018; 41(7):423-431.
IF: 1,078  
Q: 4

Aller R, Fernandez-Rodriguez C, lo Iacono O, Banares R, Abad J, Carrion JA, Garcia-Monzon C, Caballeria J, Berenguer M, Rodriguez-Peralvarez M, Miranda JL, Vilar-Gomez E, Crespo J, Garcia-Cortes M, Reig M, Navarro JM, Gallego R, Genesca J, Arias-Loste MT, Pareja MJ, Albillos A, Muntane J, Jorquera F, Sola E, Hernandez-Guerra M, Rojo MA, Salmeron J, Caballeria L, Diago M, Molina E, Bataller R, Romero-Gomez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. GASTROENTEROLOGIA Y HEPATOLOGIA. 2018; 41(5):328-349.
IF: 1,078  
Q: 4

Rebollo-Roman A, Barrera-Martin A, Alcantara-Laguna MD, Iglesias-Flores E, Canada-Sanz E, Padillo-Cuenca JC, Molina-Puertas MJ, Calanas-Continente A. Non-oropharyngeal dysphagia with frequent Emergency Room attendance. NUTRICION HOSPITALARIA. 2018; 35(4):996-998.
IF: 0,845  
Q: 4

Main Publications 2017

Requejo-Aguilar R, Alastrue-Agudo A, Cases-Villar M, et al. Combined polymer-curcumin conjugate and ependymal progenitor/stem cell treatment enhances spinal cord injury functional recovery. Biomaterials. 2017;113:18-30.
IF: 8,402
Q: 1 D: 1

Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults undergoing liver transplantation: a networkmeta-analysis. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2017.(3):-CD011639.
IF: 6,124
Q: 1 D: 1

Perez P, Rodriguez-Peralvarez M, Guerrero L, Gonzalez V, Sanchez R, Centeno M, Poyato A, Briceno J, Sanchez-Frias M, Montero JL, De la Mata M. Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. PLOS ONE. 2017.12(4):-e0175010.
IF: 2,806
Q: 1

Rodriguez-Peralvarez M, De Luca L, Crespo G, Rubin A, Marin S, Benlloch S, Colmenero J, Berenguer M, Navasa M, Tsochatzis E, De la Mata M. An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. CLINICAL TRANSPLANTATION. 2017.31(7):-e13005.
IF: 1,865
Q: 2

Puente LG, Flores EI, Benitez JM, Medina RM, Rodriguez IS, Melero PA, Aranzana MJC, Fernandez RG, Martin BM, Garcia-Sanchez V. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.GASTROENTEROLOGIA Y HEPATOLOGIA. 2017.40(9):595-604.
IF: 0,917
Q: 4

Other Publications 2017

Carrillo CF, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernandez I, Baliellas C, Carrion JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernandez-Rodriguez C, Garcia-Samaniego J, Prieto M, Bermejo MF, Salmeron J, Badia E, Salcedo M, Herrero JI, Granados R, Ble M, Marino Z, Calleja JL. Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis and Predictive Value of Model for End-Stage Liver Disease: Analysis of Data From the Hepa-C Registry. HEPATOLOGY. 2017.65(6):1810-1822.
IF: 13,246
Q: 1 D: 1

Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, Manzano ML, Lorente S, Testillano M, Xiol X, Molina E, Gonzalez-Dieguez L, Oton E, Pascual S, Santos B, Herrero JI, Salcedo M, Montero JL, Sanchez-Antolin G, Narvaez I, Nogueras F, Giraldez A, Prieto M, Forns X, Londono MC. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. JOURNAL OF HEPATOLOGY. 2017.67(6):1168-1176.
IF: 12,486
Q: 1 D: 1

Casanova MJ, Chaparro M, Garcia-Sanchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, Garcia-Lopez S, Huguet JM, Arguelles-Arias F, Aicart M, Marin-Jimenez I, Gomez-Garcia M, Munoz F, Esteve M, Bujanda L, Cortes X, Tosca J, Pineda JR, Manosa M, Llao J, Guardiola J, Perez-Martinez I, Munoz C, Gonzalez-Lama Y, Hinojosa J, Vazquez JM, Martinez-Montiel MP, Rodriguez GE, Pajares R, Garcia-Sepulcre MF, Hernandez-Martinez A, Perez-Calle JL, Beltran B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervias D, Gomollon F, et al.. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017.112(1):120-131.
IF: 9,566
Q: 1 D: 1

Chaparro M, Ramas M, Benitez JM, Lopez-Garcia A, Juan A, Guardiola J, Minguez M, Calvet X, Marquez L, Salazar LIF, Bujanda L, Garcia C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, Garcia-Sepulcre MF, Gomollon F, Piqueras M, Alcain G, Garcia-Sanchez V, Panes J, Domenech E, Garcia-Esquinas E, Rodriguez-Artalejo F, Gisbert JP. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017.112(7):1135-1143.
IF: 9,566
Q: 1 D: 1

Ordas I, Domenech E, Manosa M, Garcia-Sanchez V, Iglesias-Flores E, Penalva M, Canas-Ventura A, Merino O, Fernandez-Banares F, Gomollon F, Vera M, Gutierrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Munoz F, Aguirresarobe M, Munoz C, Fernandez L, Calvet X, Jimenez CE, Montoro MA, Mir A, De Castro ML, Garcia-Sepulcre MF, Bermejo F, Panes J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017.112(11):1709-1718.
IF: 9,566
Q: 1 D: 1

Mantzoukis K, Rodrguez-Peralvarez M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis B infection: an attempted networkmeta-analysis. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2017.(3):-CD011645.
IF: 6,124
Q:1 D:1

Lopez-Sanroman A, Vera-Mendoza I, Domenech E, Taxonera C, Ruiz VV, Marin-Jimenez I, Guardiola J, Castro L, Esteve M, Iglesias E, Ceballos D, Martinez-Montiel P, Gisbert JP, Minguez M, Echarri A, Calvet X, Barrio J, Hinojosa J, Martin-Arranz MD, Marquez-Mosquera L, Bermejo F, Rimola J, Pons V, Nos P, Spanish GETECCU Grp APPRECIA Study. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. JOURNAL OF CROHNS & COLITIS. 2017.11(11):1293-1301.
IF: 5,813
Q: 1

Ruiz-Limon P, Ortega R, De La Rosa IA, Abalos-Aguilera MD, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, Lopez-Pedrera C, Barbarroja N. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. TRANSLATIONAL RESEARCH. 2017.183():87-103.
IF: 4,652
Q: 1

Domenech E, Garcia V, Iborra M, Gutierrez A, Garcia-Lopez S, Arranz MD, Garcia-Planella E, Calvo M, Castro L, Minguez M, Taxonera C, Julia B, Cea-Calvo L, Romero C, Barreiro-de Acosta A. Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study. INFLAMMATORY BOWEL DISEASES. 2017.23(10):1840-1846.
IF: 4,525
Q: 1

Iborra M, Perez-Gisbert J, Bosca-Watts MM, Lopez-Garcia A, Garcia-Sanchez V, Lopez-Sanroman A, Hinojosa E, Marquez L, Garcia-Lopez S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltran B, Rodriguez-Gutierrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervas D, Nos P, Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU). Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients. JOURNAL OF GASTROENTEROLOGY. 2017.52(7):788-799.
IF: 4,493
Q: 1

Alonso S, Riveiro-Barciela M, Fernandez I, Rincon D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrion JA, Gomez A, Devesa MJ, Baliellas C, Castro A, Ampuero J, Granados R, Pascasio JM, Rubin A, Salmeron J, Badia E, Planas JMM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernandez-Rodriguez CM. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. JOURNAL OF VIRAL HEPATITIS. 2017.24(4):304-311.
IF: 4,122
Q: 1

D'Avola D, Cuervas-Mons V, Marti J, de Urbina JO, Llado L, Jimenez C, Otero E, Suarez F, Rodrigo JM, Gomez MA, Fraga E, Lopez P, Serrano MT, Rios A, Fabrega E, Herrero JI. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. LIVER TRANSPLANTATION. 2017.23(4):498-509.
IF: 3,91
Q: 1

Aguero F, Forner A, Valdivieso A, Blanes M, Barcena R, Manzardo C, Rafecas A, Castells L, Abradelo M, Barrera-Baena P, Gonzalez-Dieguez L, Salcedo M, Serrano T, Jimenez-Perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM, FIPSE Investigators. Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. LIVER TRANSPLANTATION. 2017.23(5):645-651.
IF: 3,91
Q: 1

Carrillo CF, Crespo G, de la Revilla J, Castells L, Buti M, Montero JL, Fabrega E, Fernandez I, Serrano-Millan C, Hernandez V, Calleja JL, Londono MC. Successful Continuation of HCV Treatment After Liver Transplantation. TRANSPLANTATION. 2017.101(5):1009-1012.
IF: 3,678
Q: 1

Rodriguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sanchez-Antolin G, Calleja JL, Molina E, Garcia-Buey ML, Blanco MA, Salmeron J, Bonet ML, Pons JA, Gonzalez JM, Casado MA, Jorquera F, group TTR. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. WORLD JOURNAL OF GASTROENTEROLOGY. 2017.23(41):7459-7469.
IF: 3,365
Q: 2

Salcedo M, Prieto M, Castells L, Pascasio JM, Alvarez JLM, Fernandez I, Sanchez-Antolin G, Gonzalez-Dieguez L, Garcia-Gonzalez M, Otero A, Lorente S, Espinosa MD, Testillano M, Gonzalez A, Castellote J, Casafont F, Londono MC, Pons JA, Perez EM, Cuervas-Mons V, Pascual S, Herrero JI, Narvaez I, Vinaixa C, Llaneras J, Sousa JM, Banares R. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. TRANSPLANT INTERNATIONAL. 2017.30(10):1041-1050.
IF: 3,079
Q: 1

Gonzalez R, De la Rosa AJ, Rufini A, Rodriguez-Hernandez MA, Navarro-Villaran E, Marchal T, Pereira S, De la Mata M, Muller-Schilling M, Pascasio-Acevedo JM, Ferrer-Rios MT, Gomez-Bravo MA, Padillo FJ, Muntane J. Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLOS ONE. 2017.12(3):-e0174326.
IF: 2,806
Q: 1

Saro C, Ceballos D, Munoz F, de-la-Coba C, Aguilar MD, Lazaro P, Garcia-Sanchez V, Hernandez M, Barrio J, de-Francisco R, Fernandez LI, Barreiro-de-Acosta M. Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2017.109(2):122-129.
IF: 1,401
Q: 4

Chaaro-Benallal D, Guerra-Veloz MF, Arguelles-Arias F, Benitez JM, Perea-Amarillo R, Iglesias E, Castro-Laria L, Sanchez-Garcia V, Maldonado-Perez B, Vilches A, Caunedo-Alvarez A, Romero-Gomez M.Evolution of the incidence of inflammatory bowel disease in Southern Spain. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2017.109(11):757-760.
IF: 1,401
Q: 4

Aguiar D, Martinez-Urbistondo D, Baroja-Mazo A, de la Mata M, Rodriguez-Peralvarez M, Rubin A, Puchades L, Serrano T, Montero J, Cuadrado A, Casafont F, Salcedo M, Rincon D, Pons JA, Herrero JI. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. ANNALS OF TRANSPLANTATION. 2017.22():265-275.
IF: 1,252
Q: 3

Fernandez-Gutierrez B, Perrotti PP, Gisbert JP, Domenech E, Fernandez-Nebro A, Canete JD, Ferrandiz C, Tornero J, Garcia-Sanchez V, Panes J, Fonseca E, Blanco F, Rodriguez-Moreno J, Carreira P, Julia A, Marsal S, Rodriguez-Rodriguez L, IMID Consortium. Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. MEDICINE. 2017.96(26):-e7308.
IF: 1,803
Q: 2

Bares LMM, Asenjo EC, Sanchez MVG, Ortega EM, Muret FRM, Moreno MVG, Bueno AMS, Flores EI, Cantero JMB, Casas JAV. SeHCAT scan in bile acid malabsorption in chronic diarrhoea. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR. 2017.36(1):37-47.
IF: 0,951
Q: 4

Pipa-Muniz M, Castells L, Pascual S, Fernandez-Castroagudin J, Diez-Miranda I, Irurzun J, Diaz-Beveridge R, Senosiain M, Arenas J, de la Mata M, Turnes J, Monge-Romero MI, Perez-Enguix D, Bustamante-Schneider J, Otegui N, Molina-Perez E, Rodriguez-Menendez JE, Varela M. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. GASTROENTEROLOGIA Y HEPATOLOGIA. 2017.40(8):515-524.
IF: 0,917
Q: 4

Gonzalez-Romo F, Picazo JJ, Rojas AG, Horrillo ML, Barrios V, Magro MC, Gregorio PG, de la Camara R, Rodriguez A, Barberan J, Martinez FB, Rufo ML, Sanz IJ, Portoles JM, Herrero FS, Arranz JE, Garcia-Sanchez V, Izquierdo MG, Mascaros E. Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update. REVISTA ESPANOLA DE QUIMIOTERAPIA. 2017.30(2):142-168.
IF: 0,75
Q: 4

Domínguez-Martín MA, Gómez-Baena G, Diez J, López-Grueso MJ, Beynon RJ, García-Fernández JM. Quantitative Proteomics Shows Extensive Remodeling Induced by Nitrogen Limitation in Prochlorococcusmarinus SS120. ED. MSYSTEMS. 2017;2(3):e00008–17–17.

Clinical Research

Active in 2019

Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico de fase III con regorafenib en pacientes con carcinoma hepatocelular (CHC) después de Sorafenib.
PI: Dr. Pilar Barrera Baena

Estudio abierto y multicéntrico para evaluar los resultados a largo plazo con ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) y ABT-333 con o sin ribavirina (RBV) en adultos con infección crónica  por el virus de la hepatitis C (VHC) de genotipo 1(TOPAZ-I).
PI: Dr. Enrique Fraga Rivas

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjets with Unresectable Hepatocellular Carcinoma.
PI: Dr. Enrique Fraga Rivas

A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn's disease.
PI: Dr. María Valle García Sánchez

Estudio de estrategias de mantenimiento comparando práctica clínica habitual frente a treat to target en pacientes con enfermedad de Crohn tratados con Ustekinumab.
PI: Dr. José Manuel Benítez Cantero

An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Crohn's Disease Active Ulcerative Colitis.
PI: Dr. José Manuel Benítez Cantero

Estudio abierto y de un solo grupo para evaluar la eficacia y la seguridad de glecaprevir (GLE)/pibrentasvir (PIB) en pacientes con infección crónica por el virus de la hepatitis C (VHC) de genotipo 1, 2, 4, 5 o 6 y cirrosis compensada no tratados previamente.
PI: Dr. José Luis Montero Alvarez

Estudio multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de ABT 494 para el tratamiento de inducción y mantenimiento en pacientes con Colitis Ulcerosa de Moderada a Grave.
PI: Dr. José Manuel Benítez Cantero

Estudio fase 3 multicéntrico, de extensión abierta, para evaluar la seguridad y eficacia a largo plazo de ABT-494 en pacientes con colitis ulcerosa.
PI: Dr. José Manuel Benítez Cantero

Estudio en fase III, aleatorizado y doble ciego de nivolumab adyuvante frente a placebo para participantes con carcinoma hepatocelular que presentan un riesgo alto de recaída después de la resección o la ablación hepática con intención curativa [Evaluación en ensayo clínico de la vía de punto de control y el nivolumab 9DX].
PI: Dr. José Luis Montero Alvarez

Estudio en fase 2a, multicéntrico, aleatorizado, comparativo con placebo, con enmascaramiento doble y grupos paralelos, para evaluar la seguridad y la eficacia de la administración oral de PRV-6527 (JNJ-40346527), un inhibidor del receptor del factor 1 estimulante de colonias, en pacientes con enfermedad de Crohn activa moderada o intensa.
PI: Dr. José Manuel Benítez Cantero

Estudio multicéntrico de fase II/III, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia del tratamiento de inducción con BI 655130 en pacientes con colitis ulcerosa activa de moderada a grave que no han respondido al tratamiento previo con fármacos biológicos.
PI: Dr. Eva Iglesias Flores

Estudio en fase II, multicéntrico y abierto, para investigar la eficacia, la seguridad y la farmacocinética del anticuerpo monoclonal anti-PD-1, BGB-A317, en pacientes con carcinoma hepatocelular irresecable tratado anteriormente.
PI: Dr. Manuel Luis Rodríguez Perálvarez

Estudio clínico multicéntrico de fase II para evaluar la seguridad y la eficacia preliminar de dos regímenes posológicos de HepaStem en pacientes con insuficiencia hepática crónica agudizada.
PI: Dr. José Luis Montero Alvarez

Estudio de inducción n.º 2: estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo, en el que se evalúa ozanimod por vía oral como tratamiento de inducción para la enfermedad de Crohn activa de moderada a grave.
PI: Dr. José Manuel Benítez Cantero

Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo, en el que se evalúa ozanimod por vía oral como tratamiento de mantenimiento para la enfermedad de Crohn activa de moderada a grave.
PI: Dr. José Manuel Benítez Cantero

Eficacia de los bolos intravenosos de corticoides más tratamiento con corticoides orales en comparación con corticoides orales en monoterapia para el tratamiento de la colitis ulcerosa moderada: ensayo clínico multicéntrico y aleatorizado. Estudio CECUM.
PI: Dr. Eva Iglesias Flores

Estudio de ampliación de fase 3, multicéntrico, sin enmascaramiento en el que se evalúa ozanimod por vía oral para la enfermedad de Crohn activa de moderada a grave.
PI: Dr. José Manuel Benítez Cantero

Estudio de induccion multicentrico, aleatorizado, doble ciego y controaldo con placebo para evaluar la eficacia y la seguridad de risakzumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta de tratamiento biologico previo.
PI: Dr. Eva Iglesias Flores

Estudio de inducción en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo sobre mirikizumab en pacientes con fracaso convencional y biológico con colitis ulcerosa activa de moderada a grave. LUCENT 1.
PI: Dr. Eva Iglesias Flores

Estudio de mantenimiento en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo sobre mirikizumab en pacientes con colitis ulcerosa activa de moderada a grave. LUCENT 2.
PI: Dr. Eva Iglesias Flores

Estudio multicentirco aleatorizado, doble ciego y controlado con placevo con tratamiento de mantenimiento durante 2 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con colitis ulcerosa que responda a la i.
PI: Dr. Eva Iglesias Flores

Estudio prospectivo para comparar la eficacia clínica de la retirada de inmunosupresión con la minimización de inmunosupresión en el trasplante hepático.
PI: Dr. Marta Guerrero Misas

Ensayo abierto y a largo plazo de la seguridad del tratamiento con BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado ensayos anteriores de BI 655130.
PI: Dr.  Eva Iglesias Flores

Identificación de biomarcadores de respuesta al tratamiento con fármacos biológicos en la enfermedad inflamatoria intestinal.
PI: Dr. Eva Iglesias Flores

Estudio de inducción multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de Upadacitinib (ABT 494) en pacientes con colitis ulcerosa de moderada a grave.
PI: Dr. José Manuel Benítez Cantero

Ensayo doble ciego, aleatorizado, controlado con placebo, fase IIb sobre la eficacia y seguridad de comprimidos de ácido norursodesoxicólico en pacientes con  esteatohepatitis no alcohólica (EHNA).
PI: Dr. Manuel Luís Rodríguez Perálvarez

Ensayo fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la combinación de quimioembolización transarterial (TACE) con durvalumab en monoterapia o con durvalumab más bevacizumab en pacientes con carcinoma hepatocelul.
PI: Dr. José Luis Montero Alvarez

Estudio abierto de fase Ib para evaluar la farmacocinética, la tolerabilidad y la seguridad de la trimetazidina oral en sujetos con insuficiencia hepática aguda sobre crónica.
PI: Dr. Manuel de la Mata García

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de CT-P13 en inyección subcutánea (CT-P13 SC) como tratamiento de mantenimiento en pacientes con enfermedad activa de Crohn de moderada a grave.
PI: Dr. José Manuel Benítez Cantero

Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de múltiples dosis y de inducción para evaluar la seguridad, la tolerabilidad y la dosis óptima de ABX464 en comparación con el placebo en pacientes con colitis ulcerosa de mo.
PI: Dr. Eva Iglesias Flores

Registro no intervencionista a largo plazo para evaluar la seguridad y la eficacia de HUMIRA (adalilumab) en pacientes con colitis ulcerosa moderamente activa y muy activa (LEGACY).
PI: Dr. Eva Iglesias Flores

EII Cáncer e infecciones Graves en Europa: I-CARE.
PI: Dr. José Manuel Benítez Cantero

Estudio prospectivo y multicentrico sobre la epidemiología y características ómicas de la enfermedad inflamatoria intestinal de reciente diagnostico en España.
PI: Dr. José Manuel Benítez Cantero

Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease.
PI: Dr. José Manuel Benítez Cantero

A post-authorization safety of golimumab in UC using spanish ENEIDA registry.
PI: Dr. José Manuel Benítez Cantero

An Observational prospective long-term exposure registry of adult patients with moderate to severe ulcerative colitis.
PI: Dr. Eva Iglesias Flores

Efecto del automanejo con dosis flexibles en pacientes con colitis ulcerosa tratados con ácido 5- aminosalicílico (5-ASA): estudio observacional controlado (Estudio ASAFLEX).
PI: Dr. Eva Iglesias Flores

REFINE: Estudio observacional de regorafenib en carcinoma hepatocelular.
PI: Dr. José Luis Montero Alvarez

Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma.
PI: Dr. Antonio Poyato González

Evaluación funcional del paciente cirrótico candidato a trasplante hepático.
PI: Dr. Manuel Luis Rodríguez Perálvarez

Efectivida y tolerabilidad de ustekinumab en la práctica clíica en pacientes con enfermedad de Crohn activa.
PI: Dr. Eva Iglesias Flores

A retrospective chart review study evaluating the longer-term effectiveness of darvadstrocel in patients who completed ADMIRE-CD.
PI: Dr. Eva Iglesias Flores

Impacto de la telemonitorización en el manejo de la enfermedad intestinal compleja en España: estudio multicéntrico TECCU.
PI: Dr. Eva Iglesias Flores

Members

Dr. Manuel de la Mata García

Principal Investigator

Dr. Jose Antonio Bárcena Ruiz

Co-Principal Investigator

Team

Patricia Aguilar Melero, Pilar Barrera Baena, Guadalupe Costán Rodero, Gustavo Ferrín Sánchez, Mª Valle García Sánchez, José Luis Montero Álvarez, Alicia Padilla Peña, José Peinado Peinado, Antonio Poyato González, Manuel Luis Rodríguez Perálvarez, Sandra González Rubio, Clara Isabel Linares Luna, Raquel Requejo Aguilar, Luis Vida Pérez, José Manuel Benítez Cantero, Rocio Fernández Gonález, Marta Guerrero Misas, Eva Iglesias Flores, Rosario Medina Medina, Encarna Díaz Sillero, Mª Isabel Gómez Núñez, Mª Isabel Salgueiro Rodríguez